- Trials with a EudraCT protocol (557)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
557 result(s) found for: Basal rate.
Displaying page 1 of 28.
EudraCT Number: 2010-019260-37 | Sponsor Protocol Number: CCRC_2010/001 | Start Date*: 2010-07-21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Cork Cancer Research Centre | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Electrochemotherapy versus conventional surgery in treatment of basal cell carcinoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Basal cell carcinoma of the skin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: IE (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003122-16 | Sponsor Protocol Number: R2810-ONC-1620 | Start Date*: 2017-09-28 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1, IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO EXPERIENCED PROGRESSION OF DISEASE ON HEDGEHOG PATHWAY INHIB... | |||||||||||||
Medical condition: Metastatic basal cell carcinoma or unresectable locally advanced basal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) AT (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004085-41 | Sponsor Protocol Number: 2007-003-0401-OPH. | Start Date*: 2009-01-15 | ||||||||||||||||
Sponsor Name:The Royal Wolverhampton Hospitals NHS Trust | ||||||||||||||||||
Full Title: Photodynamic Therapy for Basal Cell Carcinoma of the Eyelid and Periocular Skin with methyl aminolevulinate | ||||||||||||||||||
Medical condition: Periocular basal cell carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002605-62 | Sponsor Protocol Number: BCC1801 | Start Date*: 2018-10-23 | |||||||||||
Sponsor Name:Herlev and Gentofte Hospital | |||||||||||||
Full Title: Phase IIa trial with PD-L1 IO103 vaccination with montanide in patients with basal cell carcinoma. | |||||||||||||
Medical condition: basal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002508-16 | Sponsor Protocol Number: 53897 | Start Date*: 2016-08-31 | |||||||||||
Sponsor Name:Department of Dermatology D92, Bispebjerg Hospital | |||||||||||||
Full Title: Optimized photodynamic therapy for basal cell carcinoma | |||||||||||||
Medical condition: Basal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000092-33 | Sponsor Protocol Number: PDTA02_24.05.2013 | Start Date*: 2013-10-23 | |||||||||||
Sponsor Name:Medizinische Universität Wien, Univ.Klinik.f.Dermatologie | |||||||||||||
Full Title: Enhanced efficacy of photodynamic therapy in combination with 5% imiquimod -a randomised, prospective, observer-blinded study in patients with non melanoma skin cancer | |||||||||||||
Medical condition: non melanoma skin cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003305-10 | Sponsor Protocol Number: MO28295 | Start Date*: 2013-03-12 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A randomized, double-blinded, regimen controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas ... | |||||||||||||
Medical condition: Adult patients with multiple basal cell carcinomas (BCCs). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) NL (Completed) IT (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002845-40 | Sponsor Protocol Number: SP848-nBCC-1104 | Start Date*: 2012-11-15 | |||||||||||
Sponsor Name:Spirig Pharma AG | |||||||||||||
Full Title: Bi-center, open label, non-comparative trial exploring efficacy and safety of topical resiquimod gel (0.06%) in patients with nodular basal cell carcinoma (nBCC). | |||||||||||||
Medical condition: Nodular Basal Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019856-30 | Sponsor Protocol Number: CLDE225B2307 | Start Date*: 2010-06-29 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A randomized, double-blind, vehicle-controlled, multicenter trial of topically administered LDE225 cream [0.75% bid] to evaluate clearance of Basal Cell Carcinoma in adult patients with Nevoid B... | |||||||||||||
Medical condition: Basal Cell Carcinoma in adult patients with Nevoid Basal Cell Carcinoma Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004543-40 | Sponsor Protocol Number: ONC-2015-001/ML29968 | Start Date*: 2016-09-20 | |||||||||||
Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS | |||||||||||||
Full Title: A SINGLE ARM, PHASE II, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF VISMODEGIB AND RADIOTHERAPY IN PATIENTS WITH HIGH RISK OR LOCALLY ADVANCED BASAL CELL CARCINOMA NOT AMENABLE TO RADICA... | |||||||||||||
Medical condition: HIGH RISK OR LOCALLY ADVANCED BASAL CELL CARCINOMA NOT AMENABLE TO RADICAL SURGERY | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004338-13 | Sponsor Protocol Number: 2013_36 | Start Date*: 2014-12-08 | |||||||||||
Sponsor Name:CHRU De Lille | |||||||||||||
Full Title: Phase II study evaluating the interest of Vismodegib as neo-adjuvant treatment of basal cell carcinoma | |||||||||||||
Medical condition: Male and female patients at least 18 years of age with histologically confirmed diagnoses of locally advanced BCC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004945-27 | Sponsor Protocol Number: SHH4476g | Start Date*: 2009-07-09 | |||||||||||
Sponsor Name:Genentech, Inc. | |||||||||||||
Full Title: A PIVOTAL PHASE II, MULTICENTER, SINGLE ARM, TWO-COHORT TRIAL EVALUATING THE EFFICACY AND SAFETY OF GDC-0449 IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA | |||||||||||||
Medical condition: • metastatic BCC with histologic confirmation of a distant BCC metastasis (e.g., lung, liver, lymph nodes, or bone) • locally advanced BCC considered inoperable or with medical contraindication to... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000195-34 | Sponsor Protocol Number: MO25616 | Start Date*: 2011-06-21 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A single arm, open-label, phase II, multicentre study to assess the safety of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC). | |||||||||||||
Medical condition: Locally advanced or metastatic basal cell carcinoma (BCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) AT (Completed) DE (Completed) BG (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed) NL (Completed) SI (Completed) DK (Completed) HU (Completed) CZ (Completed) GR (Completed) SK (Completed) IE (Completed) PT (Completed) PL (Completed) NO (Completed) LT (Completed) FI (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002730-36 | Sponsor Protocol Number: CaEP68962 | Start Date*: 2019-11-14 | ||||||||||||||||
Sponsor Name:Department of Dermatology, Bispebjerg Hospital | ||||||||||||||||||
Full Title: Calcium electroporation for basal cell carcinomas – a ’Proof of concept’ study | ||||||||||||||||||
Medical condition: Basal cell carcinomas | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-003299-42 | Sponsor Protocol Number: PH-L19IL2TNFNMSC-04/19 | Start Date*: 2021-05-28 | |||||||||||
Sponsor Name:Philogen S.p.A. | |||||||||||||
Full Title: A phase II study of intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients with presence of injectable lesions. | |||||||||||||
Medical condition: Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC) amenable to intratumoral inje... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003241-42 | Sponsor Protocol Number: ALA-BCC-CT008 | Start Date*: 2013-12-23 | |||||||||||
Sponsor Name:Biofrontera Bioscience GmbH | |||||||||||||
Full Title: A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) in comparison to Metvix® in the treatment of non-aggressive basal cell carcin... | |||||||||||||
Medical condition: Basal cell carcinoma (BCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003502-33 | Sponsor Protocol Number: D5553C00002 | Start Date*: 2014-12-16 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel group, Phase 3 Trial to Evaluate the Safety and Efficacy of Once Weekly Exenatide Therapy Added to Titrated Basal Insulin Glarg... | |||||||||||||
Medical condition: Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001309-22 | Sponsor Protocol Number: 2593957 | Start Date*: 2021-03-29 | |||||||||||
Sponsor Name:IQVIA Commercial GmbH & Co. OHG | |||||||||||||
Full Title: Evaluation of immunological effects of the hedgehog inhibitors on basal cell carcinoma - An open label, prospective, observational biomarker study of the DeCOG. | |||||||||||||
Medical condition: Basal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022629-14 | Sponsor Protocol Number: CLDE225A2201 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A phase II, randomized double-blind study of efficacy and safety of two dose levels of LDE225 in patients with locally advanced or metastatic basal cell carcinoma | |||||||||||||
Medical condition: locally advanced or metastatic basal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GR (Prematurely Ended) GB (Prematurely Ended) ES (Completed) NL (Prematurely Ended) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000063-10 | Sponsor Protocol Number: RD.03.SPR.29040 | Start Date*: 2004-10-07 | |||||||||||
Sponsor Name:Galderma R&D | |||||||||||||
Full Title: A comparison of Metvix PDT with simple excision surgery in subjects with superficial Basal cell Carcinoma (sBCC) | |||||||||||||
Medical condition: Superficial Basal Cell Carcinomas, occurring mostly on trunk and extremities (4,5), are progressively spreading, slow growing cancers. They can be difficult to diagnose and often mistaken for oth... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
